Preclinical data suggest CHEK2 deficiency may enhance PD-1/PD-L1 response via immune microenvironment effects and higher neoantigen load, but this is not yet confirmed prospectively in RCC [72]. This evidence concerns the gene CHEK2 and renal cell carcinoma.